While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Novavax Inc. closed $11.06 below its 52-week high ($23.86), which the company achieved on June 6th.

Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...

On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.8 which represents a decrease of $-0.11 or -0.85% from the prior close of $12.91. The stock opened at $13.01 and touched a low ...

The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...

BioNTech's updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus. The ...

With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans ...

A factor that has changed over time is hospitalization due to severe COVID infections. On Aug. 1, the statewide seven-day ...

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up.